OrthoPediatrics (KIDS) Earnings Date & Reports

Key Takeaways

• OrthoPediatrics (KIDS) reported third quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, beating consensus estimates.
• The net loss narrowed to $5.9 million, or $0.25 per share, versus a loss of $11.8 million, or $0.50 per share, in the prior-year quarter.
• Non-GAAP loss per share of $0.23 was in line with analyst expectations, while revenue came in roughly $4.2 million above the consensus estimate of about $68.5 million.
• Full-year 2026 revenue guidance was raised to $270.0 million to $273.0 million, up from a prior range of $265.0 million to $269.0 million.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached a quarterly record of $6.9 million, up from $6.2 million a year earlier.
• You can explore more details on the company's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• For AI-driven market insights, explore Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

OrthoPediatrics is a medical device company focused exclusively on pediatric orthopedics, selling implants, instruments, and specialized braces across the United States and more than 75 international markets. Its third quarter 2026 results matter because they test whether the company can keep expanding revenue at a double-digit pace while closing in on a long-promised profitability inflection. Management has guided toward roughly $25 million of adjusted EBITDA and breakeven free cash flow for 2026, making each quarter's margin and cash-flow progress a key signal for investors. A record adjusted EBITDA print and a raised full-year outlook reinforce confidence that the company's specialty bracing strategy and product launches are translating growth into improving operating leverage.

Reported Results

OrthoPediatrics reported third quarter 2026 net revenue of $72.7 million, a 19% increase from $61.2 million in the prior-year period. U.S. revenue rose 19% to $57.9 million, while international revenue increased 18% to $14.8 million. Trauma and Deformity revenue grew 19% to $52.6 million, and Scoliosis revenue increased 18% to $19.2 million.

Gross profit reached $54.0 million, with a gross margin of 74%. Adjusted EBITDA climbed to a record $6.9 million, compared with $6.2 million a year earlier. Free cash flow improved to $1.6 million, versus $3.4 million used in the prior-year quarter. The net loss narrowed to $5.9 million, or $0.25 per share, from $11.8 million, or $0.50 per share, a year ago.

On a non-GAAP (non-Generally Accepted Accounting Principles) basis, the company reported a loss of $0.23 per share, matching consensus expectations. Revenue exceeded the consensus estimate of approximately $68.5 million by about $4.2 million. The company raised its full-year 2026 revenue guidance to $270.0 million to $273.0 million, representing growth of 14% to 16%, and reiterated expectations for approximately $25 million in adjusted EBITDA and breakeven free cash flow.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like OrthoPediatrics, it offers a structured way to identify comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Shares of OrthoPediatrics traded higher in the after-hours session following the report, with early indications pointing to a gain of roughly 6% as investors reacted to the revenue beat and the raised full-year guidance. The stock has meaningfully outperformed the broader Nasdaq over the course of 2026, reflecting growing optimism around the company's profitability trajectory.

Investor sentiment heading into the quarter was cautiously constructive, with attention focused on whether adjusted EBITDA was tracking toward the company's $25 million annual target. The record quarterly adjusted EBITDA figure, combined with the guidance increase, appears to have reassured the market that the company's growth strategy and specialty bracing expansion are producing tangible operating leverage.

Forward Outlook and Key Factors to Monitor

Following this earnings event, investors should watch several factors that will shape the company's trajectory into 2027. First, the raised revenue guidance of $270.0 million to $273.0 million sets a clear bar for the fourth quarter, and management's ability to deliver within that range will be closely scrutinized.

Second, the pace of adjusted EBITDA expansion remains central to the investment case. The company reiterated its target of roughly $25 million in adjusted EBITDA for 2026 and breakeven free cash flow, so quarterly progress toward those milestones will be a key signal of whether the business is truly reaching a profitability inflection.

Third, growth in the Trauma and Deformity and Scoliosis segments, along with the ongoing expansion of the OrthoPediatrics Specialty Bracing clinics, will indicate whether demand momentum can be sustained. International performance, particularly in markets outside Latin and South America, is another area worth monitoring.

Finally, investors should track cash and liquidity levels, given that cash and short-term investments declined versus the end of 2025. New product launches and set deployments will also factor into both revenue growth and capital allocation decisions in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations